All In Biotech

Drug Trial Radar · NCT01514851

Phase III Double-blind Comparative Study of BAY77-1931 (Lanthanum Carbonate) With Calcium Carbonate

Phase III Double-blind Comparative Study of BAY 77 1931 (Lanthanum Carbonate) With a Calcium Carbonate in Patients With Hyperphosphatemia Undergoing Hemodialysis

Last checked: Nov 20, 2026Latest source record: Jun 8, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 259 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

259

Actual

Start

Jan 2006

Primary completion

May 2006

Study completion May 2006

Sponsor

Lead sponsor
BayerBayer (BAYRY)
Sponsor type
Industry
First posted
Jan 23, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 20 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To assess the effect on reduction of serum phosphate and the safety of BAY77-1931 (Lanthanum Carbonate) in patients with hyperphosphatemia undergoing hemodialysis in a randomized, double-blind, parallel group study in comparison with Calcium carbonate.

Conditions

  • Hyperphosphatemia

Interventions

  • Lanthanum carbonate (BAY77-1931)Drug

  • Calcium carbonateDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in pre-dialysis serum phosphate levels (PSPL) at the end of the double-blind periodTime frame: baseline to week 8
  2. Presence/absence of incidence of hypercalcemia up to 8 weeksTime frame: up to 8 weeks

Locations

31 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Toyohashi, Aichi-ken, Japan

  • Site not named

    Yatomi, Aichi-ken, Japan

  • Site not named

    Asahi, Chiba, Japan

  • Site not named

    Chiba, Chiba, Japan

  • Site not named

    Kashiwa, Chiba, Japan

  • Site not named

    Matsudo, Chiba, Japan

  • Site not named

    Narita, Chiba, Japan

  • Site not named

    Kurume, Fukuoka, Japan

  • Site not named

    Kurume, Fukuoka, Japan

  • Site not named

    Isesaki, Gunma, Japan

  • Site not named

    Hiroshima, Hiroshima, Japan

  • Site not named

    Kobe, Hyōgo, Japan

  • Site not named

    Mito, Ibaraki, Japan

  • Site not named

    Tsuchiura, Ibaraki, Japan

  • Site not named

    Takamatsu, Kagawa-ken, Japan

  • Site not named

    Kochi, Kochi, Japan

  • Site not named

    Ōsaki, Miyagi, Japan

  • Site not named

    Sendai, Miyagi, Japan

  • Site not named

    Okayama, Okayama-ken, Japan

  • Site not named

    Suita, Osaka, Japan

  • Site not named

    Saitama, Saitama, Japan

  • Site not named

    Saitama, Saitama, Japan

  • Site not named

    Saitama, Saitama, Japan

  • Site not named

    Fuji, Shizuoka, Japan

  • Site not named

    Hamamatsu, Shizuoka, Japan

  • Site not named

    Tokushima, Tokushima, Japan

  • Site not named

    Arakawa-ku, Tokyo, Japan

  • Site not named

    Kodaira, Tokyo, Japan

  • Site not named

    Nerima-ku, Tokyo, Japan

  • Site not named

    Shibuya-ku, Tokyo, Japan

  • Site not named

    Shinjyuku-ku, Tokyo, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.